Skip to main content

Clinical Trials Using Epipodophyllotoxin Compound

Review the clinical trials studying epipodophyllotoxin compound on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 89

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Status: Active
Location: 455 locations
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Status: Active
Location: 469 locations
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Status: Active
Location: 377 locations
Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung
Status: Active
Location: 233 locations
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Status: Active
Location: 175 locations
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Status: Active
Location: 179 locations
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Status: Active
Location: 170 locations
Dinutuximab with Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children with Newly Diagnosed High Risk Neuroblastoma
Status: Active
Location: 153 locations
A Study Using Risk Factors to Determine Treatment for Children with Favorable Histology Wilms Tumors (FHWT)
Status: Active
Location: 139 locations
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)
Status: Active
Location: 146 locations
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Status: Active
Location: 145 locations
A Study of Lower Radiotherapy Dose to Treat Children with CNS Germinoma
Status: Active
Location: 89 locations
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Status: Active
Location: 89 locations
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma
Status: Active
Location: 16 locations
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Status: Active
Location: 19 locations
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
Status: Active
Location: 10 locations
A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma
Status: Active
Location: 10 locations
Molecular and Clinical Risk Directed Therapy for Infants and Young Children with Newly Diagnosed Medulloblastoma
Status: Active
Location: 10 locations
Mogamulizumab with DA-EPOCH for the Treatment of Aggressive T-cell Non-Hodgkin Lymphoma
Status: Active
Location: 9 locations
Abbreviated Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone for the Treatment of Stage IIB-IV Hodgkin Lymphoma
Status: Active
Location: 8 locations
Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Location: 8 locations
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
Status: Active
Location: 9 locations
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma
Status: Active
Location: 7 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
Status: Active
Location: 7 locations
Mitotane with or without Cisplatin and Etoposide after Surgery in Treating Patients with Stage I-III Adrenocortical Cancer with High Risk of Recurrence
Status: Active
Location: 3 locations